NL-OMON37545
Not yet recruiting
Not Applicable
Biobanking, identification of biomarkers and the study on immune system in patients with multiple sclerosis - MS biobank
niversitair Medisch Centrum Sint Radboud0 sites2,000 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- multiple sclerosis
- Sponsor
- niversitair Medisch Centrum Sint Radboud
- Enrollment
- 2000
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-Individuals must be at least 18 years old and able to give informed consent.
- •\-Individuals must have one of the diagnoses: clinically isolated syndrom, relapsing\-remitting MS, primary progressive MS, secondary progressive MS, neuromyelitis optica, transverse myelitis, and radiologically isolated syndrome.
- •\-Individuals must be willing and able to provide blood and/or cerebrospinal fluid in addtion to requirement for clinical analysis
Exclusion Criteria
- •\-Patients currently diagnosed with an autoimmune disorder other than MS.
- •\-Patients with ongoing bacterial, viral, or fungal infection.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Verification and identification of new biomarkers for intestinal barrier functioHealthy AdultsJPRN-UMIN000051426Meiji Co., Ltd.149
Completed
Not Applicable
HELPFulDiastolic dysfunction of the heart, eventually evolving into heart failure with preserved ejection fraction, Coronary vascular disease, including both macro- and microvascular coronary diseaseNL-OMON21717nvt3,000
Completed
Not Applicable
Discovery and validation of diagnostic biomarkers for left ventricular diastolic dysfunction and HEart faiLure with Preserved ejection FractioDiastolic Heart FailureHeart failure with preserved ejection fraction10019280NL-OMON50536niversitair Medisch Centrum Utrecht977
Active, not recruiting
Phase 1
Biomarker driven treatment for patients less than 65 years with aggressive B-cell lymphomaEUCTR2015-002846-30-SEHUS-The Hospital District of Helsinki and Uusimaa120
Active, not recruiting
Phase 1
Biomarker driven treatment for patients less than 65 years with aggressive B-cell lymphomaDiffuse large B-cell lymphomaMedDRA version: 21.0 Level: PT Classification code 10012818 Term: Diffuse large B-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-002846-30-DKHUS-The Hospital District of Helsinki and Uusimaa120